ArticleCancer research2017
Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response.Clinical and experimental medicine · 2020Trial
- Preclinical Study of Radiolabeled LyP-1 for Detecting Sunitinib-induced Changes in the Tumor Microenvironment and Synergistic Antitumor Effects in Triple-negative Breast Cancer.Molecular imaging and biology · 2026Article
- Potential mechanisms and clinical applications of static magnetic field therapy in glioma.Frontiers in neurology · 2025Review
- Prediction of the response to antiangiogenic sunitinib therapy by non-invasive hybrid diffuse optics in renal cell carcinoma.Biomedical optics express · 2024Article
- IONPs-Based Medical Imaging in Cancer Care: Moving Beyond Traditional Diagnosis and Therapeutic Assessment.International journal of nanomedicine · 2023Review
- MiRNA-124 regulates the sensitivity of renal cancer cells to cisplatin-induced necroptosis by targeting the CAPN4-CNOT3 axis.Translational andrology and urology · 2021Article
- Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer.Cancer research · 2021Review
- Choosing The Right Animal Model for Renal Cancer Research.Translational oncology · 2020Review
- A New Highlight ofCells · 2020Article
- Flaming the fight against cancer cells: the role of microRNA-93.Cancer cell international · 2020Review
- MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment.Cancer research · 2019Article
- Patient-specific organotypic blood vessels as an in vitro model for anti-angiogenic drug response testing in renal cell carcinoma.EBioMedicine · 2019Article
- Diffusion-Weighted MRI Is Insensitive to Changes in the Tumor Microenvironment Induced by Antiangiogenic Therapy.Translational oncology · 2018Article
- Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology.Radiology · 2018Article
- The expression and function of RASAL2 in renal cell carcinoma angiogenesis.Cell death & disease · 2018Article
- DCE-MRI of Sunitinib-Induced Changes in Tumor Microvasculature and Hypoxia: A Study of Pancreatic Ductal Adenocarcinoma Xenografts.Neoplasia (New York, N.Y.) · 2018Article
- Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.Science (New York, N.Y.) · 2018Article
- miR-93-3p inhibition suppresses clear cell renal cell carcinoma proliferation, metastasis and invasion.Oncotarget · 2017Article
- Kidney cancer: FBV indicates sunitinib response.Nature reviews. Urology · 2017Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
Abstract
Antiangiogenic therapy is efficacious in metastatic renal cell carcinoma (mRCC). However, the ability of antiangiogenic drugs to delay tumor progression and extend survival is limited, due to either innate or acquired drug resistance. Furthermore, there are currently no validated biomarkers that predict which mRCC patients will benefit from antiangiogenic therapy. Here, we exploit susceptibility contrast MRI (SC-MRI) using intravascular ultrasmall superparamagnetic iron oxide particles to quantify and evaluate tumor fractional blood volume (fBV) as a noninvasive imaging biomarker of response to the antiangiogenic drug sunitinib. We also interrogate the vascular phenotype of RCC xenografts exhibiting acquired resistance to sunitinib. SC-MRI of 786-0 xenografts prior to and 2 weeks after daily treatment with 40 mg/kg sunitinib revealed a 71% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.